Metvix (Methyl Aminolevulinate)

Methyl aminolevulinate is a prodrug that penetrates keratinocytes and is converted intracellularly to protoporphyrin IX. When the treated skin is illuminated with red light (approximately 630 nm), protoporphyrin IX generates reactive oxygen species that cause selective cytotoxicity of abnormal cells while sparing normal tissue.

The prescribed dose of Metvix is determined by the treating physician. Typically, a thin layer of the 0.2 % w/w cream is applied to the target area and left in place for a specified incubation period before illumination. Exact amount, frequency, and illumination parameters are individualized.

Safety data for methyl aminolevulinate during pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the prescriber should evaluate each case.

To request Metvix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature control) and assistance with import documentation.

Metvix belongs to the photodynamic therapy class, whereas alternative options include topical 5‑fluorouracil, imiquimod, diclofenac gel, or cryotherapy. Photodynamic therapy offers field‑directed treatment of multiple lesions with a short treatment course, but requires a light‑activation step and may cause transient local reactions compared with purely topical agents.

Metvix should be stored at room temperature, below 25 °C, in its original container. The packaging protects the cream from light and moisture; therefore it should be kept tightly closed and stored away from direct sunlight or excessive heat to maintain stability.

Metvix is applied topically as a thin, even layer to the cleaned, dry skin area affected by actinic keratosis. After a prescribed incubation period (usually a few hours), the treated area is illuminated with a red‑light source by a healthcare professional to activate the photosensitizer.

The most serious adverse events include severe photosensitivity reactions, allergic contact dermatitis, and secondary infection of the treated site. Patients should be monitored for excessive pain, extensive erythema, or signs of infection, and treatment should be discontinued if serious reactions occur.

Metvix is contraindicated in individuals with known hypersensitivity to methyl aminolevulinate or any component of the formulation, and it should be avoided on mucous membranes or broken skin. Patients with active skin infections, uncontrolled photosensitivity disorders, or those unable to comply with light‑avoidance precautions should not be treated with Metvix.